<DOC>
	<DOCNO>NCT00130403</DOCNO>
	<brief_summary>To determine prior therapy alendronate risedronate postmenopausal woman osteoporosis influence clinical effectiveness teriparatide ; The primary objective study compare teriparatide ( human , recombinant PTH [ 1-34 ] ) -associated change baseline marker bone formation , N-terminal propeptide type I collagen ( P1NP ) , subject previously treat risedronate previously treat alendronate .</brief_summary>
	<brief_title>OPTAMISE : Clinical Effectiveness Teriparatide After Alendronate Risedronate Therapy Osteoporotic Postmenopausal Women</brief_title>
	<detailed_description>All subject treat teriparatide ( human , recombinant PTH [ 1-34 ] ) ( human , recombinant PTH [ 1-34 ] ) , 20 microgram subcutaneously daily 12 month . Subjects consist 290 postmenopausal woman previously treat either risedronate alendronate least 24 month . An approximately equal number subject previously treat risedronate alendronate , subject balance regard duration previous treatment .</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<mesh_term>Alendronate</mesh_term>
	<mesh_term>Teriparatide</mesh_term>
	<mesh_term>Risedronate Sodium</mesh_term>
	<mesh_term>Etidronic Acid</mesh_term>
	<criteria>ELIGIBILITY CRITERIA include : Postmenopausal woman use risedronate alendronate continuously least 24 mos prior enrollment Dosing regimen allowable continuous ( ie , uninterrupted ) daily weekly formulation risedronate ( 5 mg daily [ OD ] 35 30 mg week [ OAW ] ) alendronate ( 10 mg OD 70 mg OAW ) , minimum 24 month prior enrollment study Lumbar spine total hip BMD Tscore 1ess equal 2.0 &gt; /= 1 prevalent osteoporotic fracture , lumbar spine total hip BMD Tscore less equal 2.5 without &gt; /= 1 prevalent osteoporotic fracture . The qualify value must document prior enrollment Vitamin D ( 25hydroxyvitamin D ) 16 ng/ml 80 ng/ml Urine NTX &lt; 50 nmol/mmol creatinine ( assure treatment compliance bone turnover premenopausal range ) EXCLUSION CRITERIA include : Impaired renal function , demonstrate creatinine clearance &lt; 30 ml/min Any condition disease may interfere evaluation least 2 lumbar vertebra ( necessarily contiguous ) , determine screen radiograph radiologist central facility ( eg , confluent aortic calcification , severe osteoarthritis , spinal fusion , lumbar spine fracture ) Depot injection vitamin D &gt; 10,000 IU past 9 month prior start investigational product Treatment antiresorptive agent risedronate , alendronate , hormone replacement therapy within last 36 month study entry ( ie , ibandronate , pamidronate , etidronate , raloxifene , clodronate , zoledronate ) Use combination alendronate risedronate , either simultaneously sequentially , within 60 month prior enrollment , use antiresorptive agent combination risedronate alendronate</criteria>
	<gender>Female</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2011</verification_date>
</DOC>